Atrial fibrillation and stroke: four treatment controversies

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Atrial fibrillation is a major cause of ischemic stroke.
• Warfarin is the standard anticoagulant for stroke prevention in high-risk patients.
• Novel oral anticoagulants like ximelagatran show promise but face regulatory hurdles due to safety concerns.

Purpose of the Study:

• To evaluate the efficacy and safety of anticoagulation strategies for stroke prevention in atrial fibrillation.
• To assess the utility of the CHADS2 score for identifying low-risk patients.
• To determine optimal International Normalized Ratio (INR) targets and the role of aspirin in conjunction with anticoagulation.

Main Methods:

• Review of clinical trial data comparing warfarin with novel oral anticoagulants.
• Analysis of stroke risk stratification using the CHADS2 scheme.
• Evaluation of bleeding risks associated with different anticoagulation regimens and aspirin co-administration.

Main Results:

• Ximelagatran is clinically equivalent to warfarin for stroke prevention but has potential hepatic toxicity concerns.
• The CHADS2 score effectively identifies atrial fibrillation patients who may not benefit from anticoagulation.
• A lower INR target (1.6-2.5) may be suitable for primary prevention in patients over 75.
• Adding aspirin to anticoagulation increases bleeding risk, including central nervous system bleeds.

Conclusions:

• Warfarin remains a key therapy for high-risk atrial fibrillation patients.
• Risk stratification tools like CHADS2 are crucial for personalized anticoagulation decisions.
• Careful consideration of INR targets and the risks of combining anticoagulants with aspirin is essential for optimizing patient safety and efficacy.